Every 10-Q that IN8bio, Inc. (INAB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow INAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INAB filings page.
IN8bio, Inc., a clinical-stage gamma-delta T cell immunotherapy company, reported a net loss of $4.8 million for the quarter and $9.9 million for the six months ended June 30, 2026, modestly improved from the prior-year periods as both research and development and general and administrative expenses declined slightly.
Cash and restricted cash totaled $18.1 million at June 30, 2026, with net cash used in operating activities of $8.7 million in the first half. Management states that existing cash of $18.0 million is expected to fund operations only into April 2027 and explicitly notes substantial doubt about the company’s ability to continue as a going concern without additional capital.
The pipeline centers on INB-100 for high‑risk leukemias, DeltEx DRI candidates INB-200/400 for glioblastoma, and the INB-600 T cell engager platform, including INB-619 for CD19‑positive autoimmune disease. Future funding may come from equity or debt financing, strategic collaborations, and up to $29.1 million of potential warrant and milestone proceeds, none of which are assured.
IN8bio, Inc. reports Q1 2026 results and highlights substantial doubt about its ability to continue as a going concern. The clinical-stage biotech posted a net loss of $5.1 million, slightly improved from $5.6 million a year earlier, as operating expenses fell to $5.3 million.
Cash was $21.9 million as of March 31, 2026, which management expects to fund operations only into April 2027. With an accumulated deficit of $146.2 million and no product revenue, the company plans to prioritize its pipeline, seek additional equity or debt financing, and pursue collaborations.
IN8bio’s programs include INB-100 for high-risk leukemias, INB-200/400 for glioblastoma, and INB-619, a CD19-targeted T cell engager for autoimmune diseases, though several preclinical efforts remain paused to conserve cash.
IN8bio (INAB) filed its Q3 2025 10‑Q, reporting smaller losses as it cut costs and refocused its pipeline. Net loss was $3.9 million for the quarter, an improvement from $7.1 million a year ago, as total operating expenses fell to $4.0 million from $7.1 million. Year-to-date net loss was $14.5 million.
Cash was $10.7 million as of September 30, 2025. The company disclosed “substantial doubt” about its ability to continue as a going concern, noting current cash is not expected to fund operations for 12 months. During the nine months, IN8bio raised approximately $8.5 million via its ATM program and continued to manage expenses.
The company executed a 1‑for‑30 reverse stock split in June 2025. Shares outstanding were 4,589,196 at September 30, 2025, and 4,634,396 as of November 3, 2025. Pipeline updates include continued encouraging INB‑100 AML data and the previously announced suspension of INB‑400 Phase 2 enrollment to conserve cash.